Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
Authors:
Open Access
- 2 November 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (11) , e48372
Abstract
Assessment of tumor size changes is crucial in clinical trials and patient care. We compared imatinib-induced volume changes of liver metastases (LM) from gastro-intestinal stromal tumors (GIST) to RECIST and Choi criteria and their association with overall survival (OS). LM from 84 GIST patients (training and validation set) were evaluated using manual and semi-automated Computed Tomography measurements at baseline, after 3, 6 and 12 months of imatinib. The ability of uni-dimensional (1D) and three-dimensional (3D) measurements to detect size changes (increase/decrease) ≥20% was evaluated. Volumetric response cut-offs were derived from minimally relevant changes (+20/−30%) by RECIST, considering lesions as spherical or ellipsoidal. 3D measurements detected size changes ≥20% more frequently than 1D at every time-point (P≤0.008). 3D and Choi criteria registered more responses than RECIST at 3 and 6 months for 3D-spheres (P≤0.03) and at all time-points for 3D-ellipsoids and Choi criteria (P<0.001). Progressive disease by 3D criteria seems to better correlate to OS at late time-points than other criteria. Volume criteria (especially ellipsoids) classify a higher number of patients as imatinib-responders than RECIST. Volume discriminates size changes better than diameter in GIST and constitutes a feasible and robust method to evaluate response and predict patient benefit.Keywords
This publication has 46 references indexed in Scilit:
- Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2Clinical Pharmacology & Therapeutics, 2011
- Virtual Liver Resection and Volumetric Analysis of the Future Liver Remnant using Open Source Image Processing SoftwareWorld Journal of Surgery, 2010
- Semi-Automated Quantification of Hepatic Lesions in a PhantomInvestigative Radiology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- OsiriX: An Open-Source Software for Navigating in Multidimensional DICOM ImagesJournal of Digital Imaging, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958